Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance
Daxor Corporation (DXR) has expanded its blood volume analysis (BVA) capabilities by adding three new medical centers to its network. The expansion is driven by the company's ezBVA Lab service, a CLIA-certified facility that provides precise blood volume analysis results within 24 hours. The new adoptions include a leading regional referral center in Philadelphia's northern suburbs, a premier northern Kentucky hospital, and an Arkansas community hospital.
The ezBVA Lab service operates on a zero-capital investment model with full reimbursement coverage, making it an attractive solution for healthcare providers. All three facilities will implement the service primarily for outpatient heart failure management, with potential for inpatient expansion.
Daxor Corporation (DXR) ha ampliato le sue capacità di analisi del volume ematico (BVA) aggiungendo tre nuovi centri medici alla sua rete. Questa espansione è guidata dal servizio ezBVA Lab dell'azienda, una struttura certificata CLIA che fornisce risultati precisi di analisi del volume ematico entro 24 ore. Le nuove adesioni includono un importante centro di riferimento regionale nei sobborghi settentrionali di Philadelphia, un ospedale di primo piano nel nord del Kentucky e un ospedale comunitario in Arkansas.
Il servizio ezBVA Lab opera con un modello a zero investimenti di capitale e copertura completa del rimborso, rendendolo una soluzione interessante per i fornitori di assistenza sanitaria. Tutte e tre le strutture implementeranno il servizio principalmente per la gestione ambulatoriale dell'insufficienza cardiaca, con potenziale espansione per il ricovero ospedaliero.
Daxor Corporation (DXR) ha ampliado sus capacidades de análisis de volumen sanguíneo (BVA) incorporando tres nuevos centros médicos a su red. Esta expansión está impulsada por el servicio ezBVA Lab de la compañía, una instalación certificada por CLIA que ofrece resultados precisos de análisis de volumen sanguíneo en 24 horas. Las nuevas incorporaciones incluyen un centro de referencia regional líder en los suburbios del norte de Filadelfia, un hospital destacado en el norte de Kentucky y un hospital comunitario en Arkansas.
El servicio ezBVA Lab funciona con un modelo sin inversión de capital y con cobertura total de reembolso, lo que lo convierte en una solución atractiva para los proveedores de atención médica. Las tres instalaciones implementarán el servicio principalmente para el manejo ambulatorio de la insuficiencia cardíaca, con posibilidad de expansión para pacientes hospitalizados.
Daxor Corporation (DXR)는 혈액량 분석(BVA) 역량을 확장하여 네트워크에 세 개의 새로운 의료 센터를 추가했습니다. 이번 확장은 회사의 ezBVA Lab 서비스에 의해 추진되었으며, 이 서비스는 CLIA 인증을 받은 시설로 24시간 내에 정확한 혈액량 분석 결과를 제공합니다. 새로 추가된 기관은 필라델피아 북부 교외의 주요 지역 진료 센터, 켄터키 북부의 대표 병원, 그리고 아칸소의 지역 병원입니다.
ezBVA Lab 서비스는 자본 투자 없이 전액 환급이 가능한 모델로 운영되어 의료 제공자들에게 매력적인 솔루션입니다. 세 기관 모두 주로 외래 심부전 관리에 이 서비스를 도입하며, 입원 환자 확대 가능성도 있습니다.
Daxor Corporation (DXR) a renforcé ses capacités d'analyse du volume sanguin (BVA) en ajoutant trois nouveaux centres médicaux à son réseau. Cette expansion est portée par le service ezBVA Lab de l'entreprise, un laboratoire certifié CLIA qui fournit des résultats précis d'analyse du volume sanguin en 24 heures. Les nouvelles intégrations comprennent un centre de référence régional majeur dans la banlieue nord de Philadelphie, un hôpital de premier plan dans le nord du Kentucky, ainsi qu'un hôpital communautaire en Arkansas.
Le service ezBVA Lab fonctionne selon un modèle sans investissement en capital avec une prise en charge complète du remboursement, ce qui en fait une solution attrayante pour les prestataires de soins de santé. Les trois établissements mettront en œuvre ce service principalement pour la gestion ambulatoire de l'insuffisance cardiaque, avec un potentiel d'extension aux patients hospitalisés.
Daxor Corporation (DXR) hat seine Fähigkeiten zur Blutvolumenanalyse (BVA) erweitert, indem drei neue medizinische Zentren in sein Netzwerk aufgenommen wurden. Die Expansion wird durch den ezBVA Lab Service des Unternehmens vorangetrieben, eine CLIA-zertifizierte Einrichtung, die präzise Blutvolumenergebnisse innerhalb von 24 Stunden liefert. Zu den neuen Einrichtungen gehören ein führendes regionales Überweisungszentrum in den nördlichen Vororten von Philadelphia, ein erstklassiges Krankenhaus im Norden von Kentucky und ein Gemeinschaftskrankenhaus in Arkansas.
Der ezBVA Lab Service arbeitet nach einem Modell ohne Kapitalinvestitionen mit vollständiger Kostenerstattung, was ihn für Gesundheitsdienstleister attraktiv macht. Alle drei Einrichtungen werden den Service hauptsächlich für das ambulante Management von Herzinsuffizienz einsetzen, mit Potenzial für eine Ausweitung auf stationäre Patienten.
- Expansion into three new medical centers indicates growing market acceptance
- Zero-capital investment model and full reimbursement coverage reduces adoption barriers
- Quick 24-hour turnaround time for blood volume analysis results enhances operational efficiency
- Potential for inpatient expansion at the Philadelphia facility suggests growth opportunities
- None.
Daxor’s Innovative ezBVA Lab Service Drives Accessibility and Operational Efficiency
Oak Ridge, TN, May 06, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant expansion of its blood volume analysis (BVA) capabilities in three new hospitals. This growth is accelerated by the widespread adoption of Daxor's ezBVA Lab service – a cutting-edge, CLIA-certified facility delivering precise, on-demand blood volume analysis results within 24 hours. This diagnostic solution has driven strong sales momentum as healthcare providers embrace the clinical and economic benefits of Daxor's innovative technology.
Recent sales wins include:
- Leading regional referral center in Philadelphia's northern suburbs implementing ezBVA Lab service for outpatient heart failure management with planned inpatient expansion
- Premier northern Kentucky hospital adopting ezBVA Lab service to enhance outpatient heart failure diagnostic capabilities
- Arkansas community hospital (part of larger healthcare network) integrating ezBVA Lab service to optimize outpatient heart failure treatment protocols
"Our ezBVA Lab service has become a breakthrough solution, eliminating traditional barriers with its zero-capital investment model and full reimbursement coverage. Healthcare providers nationwide are embracing our BVA technology as they recognize its critical role in improving patient outcomes while optimizing operational efficiency," stated Michael Feldschuh, Daxor CEO and President.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 70,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What is Daxor's ezBVA Lab service and how does it work?
Which new medical centers have adopted Daxor's (DXR) blood volume analysis technology?
How long does it take to get results from Daxor's ezBVA Lab service?
What is the primary medical application for Daxor's (DXR) blood volume analysis technology?
What are the financial benefits of Daxor's ezBVA Lab service for healthcare providers?
